Apellis Pharmaceuticals (APLS) News Today $19.91 +0.47 (+2.42%) Closing price 04:00 PM EasternExtended Trading$20.07 +0.16 (+0.80%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300MJuly 9, 2025 | finance.yahoo.comKBC Group NV Sells 100,437 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)July 9, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 9, 2025 | marketbeat.comMorgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold RatingJuly 6, 2025 | msn.comWilliam Blair Has Positive Forecast for APLS Q3 EarningsJuly 6, 2025 | americanbankingnews.comWedbush Issues Optimistic Outlook for APLS EarningsJuly 6, 2025 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $26.00July 5, 2025 | americanbankingnews.comWedbush Predicts Lower Earnings for Apellis PharmaceuticalsJuly 5, 2025 | americanbankingnews.comAnalysts Set Expectations for APLS FY2025 EarningsJuly 4, 2025 | marketbeat.comWedbush Equities Analysts Raise Earnings Estimates for APLSJuly 4, 2025 | marketbeat.comWilliam Blair Analysts Lift Earnings Estimates for APLSJuly 4, 2025 | marketbeat.comZacks Research Has Bullish Estimate for APLS Q3 EarningsJuly 4, 2025 | americanbankingnews.comApellis Pharmaceuticals Secures $275M Royalty Buy-Down DealJuly 3, 2025 | theglobeandmail.comWedbush Has Bearish Estimate for APLS FY2028 EarningsJuly 3, 2025 | marketbeat.comWilliam Blair Has Negative Forecast for APLS Q4 EarningsJuly 3, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market MispricingJuly 2, 2025 | insidermonkey.com5APLS : What 13 Analyst Ratings Have To Say About Apellis PharmaceuticalsJuly 2, 2025 | benzinga.comMorgan Stanley Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) StockJuly 2, 2025 | marketbeat.comZacks Research Issues Optimistic Forecast for APLS EarningsJuly 2, 2025 | marketbeat.comApellis stock surges after Sobi $300 million royalty dealJuly 1, 2025 | msn.comApellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)July 1, 2025 | finance.yahoo.comApellis signs royalty purchase deal with Sobi for AspaveliJuly 1, 2025 | msn.comSobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)July 1, 2025 | prnewswire.comApellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)July 1, 2025 | globenewswire.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by Wealth Enhancement Advisory Services LLCJuly 1, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (APLS) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comApellis Pharmaceuticals Inc News (APLS) - Investing.comJune 24, 2025 | investing.comDavid O. Watson Sells 5,000 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockJune 19, 2025 | insidertrades.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 5,000 SharesJune 18, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assenagon Asset Management S.A.June 18, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.4% - What's Next?June 16, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 14, 2025 | marketbeat.comSG Americas Securities LLC Grows Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)June 12, 2025 | marketbeat.comPallas Capital Advisors LLC Grows Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)June 11, 2025 | marketbeat.comEquities Analysts Offer Predictions for APLS FY2026 EarningsJune 10, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Merit Financial Group LLCJune 9, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Has $1.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)June 9, 2025 | marketbeat.comApellis, Sobi present data from open-label period of Phase 3 VALIANT studyJune 7, 2025 | finance.yahoo.comHennion & Walsh Asset Management Inc. Grows Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)June 7, 2025 | marketbeat.comApellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGNJune 6, 2025 | globenewswire.comApellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Up 7.7% Following Analyst UpgradeJune 3, 2025 | marketbeat.comWhy Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On MondayJune 3, 2025 | msn.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $29.00June 2, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 2, 2025 | marketbeat.comWhat is Zacks Research's Forecast for APLS Q2 Earnings?May 31, 2025 | marketbeat.comToronto Dominion Bank Has $31.82 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)May 28, 2025 | marketbeat.comVoloridge Investment Management LLC Reduces Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)May 27, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Squarepoint Ops LLCMay 27, 2025 | marketbeat.comNuveen Asset Management LLC Has $15.67 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)May 27, 2025 | marketbeat.com Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Media Mentions By Week APLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.931.01▲Average Medical News Sentiment APLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼49▲APLS Articles Average Week Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BPMC News BBIO News VRNA News ROIV News ELAN News RVMD News LEGN News GRFS News TGTX News NUVL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLS Stock Alerts